Aug 7 (Reuters) - Takeda Pharmaceutical Co Ltd:
* NOVAVAX AND TAKEDA ANNOUNCE COLLABORATION FOR NOVAVAX' COVID-19 VACCINE CANDIDATE IN JAPAN
* SEES CAPACITY TO MANUFACTURE OVER 250 MILLION DOSES OF COVID-19 VACCINE PER YEAR
* NOVAVAX & TAKEDA TO PARTNER FOR DEVELOPMENT, MANUFACTURING AND COMMERCIALIZATION OF NVX-COV2373 IN JAPAN
* NOVAVAX WILL LICENSE & TRANSFER MANUFACTURING TECHNOLOGIES TO ENABLE TAKEDA TO MANUFACTURE VACCINE ANTIGEN
* TO RECEIVE FUNDING FROM JAPAN'S MINISTRY OF HEALTH, LABOUR AND WELFARE TO SUPPORT MANUFACTURING Source text https://bit.ly/2Ca25GQ Further company coverage: